10:11 AM EDT, 04/29/2024 (MT Newswires) -- Merck ( MRK ) said Monday that a phase 3 study of its investigational 21-valent pneumococcal vaccine V116 showed that it had "noninferior" immune responses to 12 common serotypes compared to the 23-valent PPSV23 vaccine.

The company said that V116 also showed "superior" immune responses for nine unique serotypes included in V116 but not in PPSV23. The vaccine had a safety profile similar to PPSV23, Merck ( MRK ) added.

V116 is currently being evaluated by the US Food and Drug Administration and the European Medicines Agency, Merck ( MRK ) said,

Price: 131.52, Change: +0.32, Percent Change: +0.24